The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea—but competition has intensified since the U.S. approval of Novartis’s Beovu in late 2019. We expect this launch to be followed by six other late-phase therapies for wet AMD, and biosimilars are on the horizon; thus, Eylea's and Lucentis’s positions will be increasingly threatened as the market becomes more fragmented. In contrast to the treatment of wet AMD, management of patients with dry AMD is limited to minimally effective vitamin formulations because no prescription therapies are approved for this large and underserved subpopulation. However, several novel therapies are advancing in the pipeline for dry AMD, increasing the possibility that an effective therapy may soon emerge.
- Do KOLs perceive any differences between Avastin, Eylea, Lucentis, and Beovu? How is the wet AMD treatment algorithm expected to change, if at all, as new products launch?
- Biosimilar versions of Eylea and Lucentis are forecast to launch within the next five years. What is the likely impact of these therapies on current and emerging VEGF inhibitors?
- A substantial unmet need in wet AMD exists for therapies with longer dosing intervals than those offered by current therapies. To what extent are late-phase therapies such as Roche’s ranibizumab port delivery system and faricimab expected to capitalize on this unmet need?
- With the anticipated approval of Apellis’s pegcetacoplan and IVERIC bio's Zimura as the first drugs for GA, how likely will these complement inhibitors be incorporated into clinical practice?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2029, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III / PR: 10 drugs; Phase II: 13 drugs; coverage of select Phase I products.
- Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Thomas Cronin; Emma McFadden, PhD
Since joining DRG in late 2019, Tom has worked on reports focusing on psychiatric and ophthalmologic disorders for the CNS team. His background is in biochemistry and he previously worked in the intellectual property field as a registered Patent Agent. Prior to joining DRG, Tom was an Intellectual Property Manager in a Boston-based biopharmaceutical company focusing on treating metabolic diseases and disorders. He has also worked for several internationally recognized law firms representing corporate and institutional clients in all matters of life science – related intellectual property.
Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy.
Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.